Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

Keyword: brca

81 through 90 of 120

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Does expanded genetic testing benefit Jewish women diagnosed with breast cancer?

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Jewish women with breast cancer who previously tested negative for the three most common BRCA mutations

BRCA1 and BRCA2 mutations are common in people of Eastern European (Ashkenazi) Jewish descent. About 2% of all Ashkenazi Jewish people will test positive for one of three common mutations in these genes. Genetic testing for Jewish people sometimes focuses on only the three most common mutations. For Jewish women with breast cancer, little is known about their chance of carrying a different hereditary mutation that may increase risk. This study looked at expanded genetic testing in Jewish women diagnosed with breast cancer to learn how often they carried mutations other than the three most common BRCA gene mutations found in Ashkenazi Jewish people. (09/13/17)

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : New cancer risk estimates for BRCA1/2 mutation carriers

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women with an inherited mutation in BRCA1 or BRCA2

Cancer risk estimates for BRCA1 and BRCA2 mutation carriers are important because they impact patient decision-making. Until now, almost all risk estimates for mutation carriers were based on results of retrospective studies that looked back on mutation carriers who had cancer. This new study is prospective—it followed almost 10,000 BRCA mutation carriers without cancer to see if or when they developed breast or ovarian cancer. The cancer risk estimates of this study may be more accurate because it followed mutation carriers who did not have cancer over time. (7/28/17)

Read More

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Article : Can your breast cancer come back?

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Most relevant for:

Elaine Howley’s piece for US News & World Report, “Can My Breast Cancer Come Back?” examines a common misperception that many breast cancer patients have after completing treatment, and explains what can actually occur. (7/25/17)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

View Related Clinical Trials

Study : Gaps in genetic testing and decision-making for women with early-stage breast cancer

Relevance: Medium-High

Strength of Science: Medium-High

View Related Clinical Trials

Most relevant for: People diagnosed with early stage breast cancer

Genetic testing for cancer risk is now more affordable and easier to obtain. As a result, many breast cancer patients are tested without ever seeing a genetic counselor. Genetic testing results affect treatment decision making, but they can be confusing, especially if patients do not receive genetic counseling. This study looks at breast cancer patients’ experiences following genetic testing and how testing results affect surgical decision making. (7/14/17)

Read More

Relevance: Medium-High

Strength of Science: Medium-Low

Study : Routine breast cancer screening leads to overdiagnosis

Relevance: Medium-High

Strength of Science: Medium-Low

Most relevant for: Women at average risk for breast cancer

Routine breast cancer screening for women of average risk has been controversial for many years because some believe that the benefits do not outweigh the risks. Recent headlines covering a study in Denmark suggests that routine breast cancer screening leads to “overdiagnosis” of breast cancer. (4/4/17)

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Patient experiences with genetic testing

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women diagnosed with early-stage breast cancer

Patients can now find out if they have a mutation in more than 20 different genes that are associated with cancer risk, thanks to research advances and the decreasing cost of genetic testing. However, patients’ experiences and use of genetic counseling and testing with these changes are unknown. Do patients want genetic testing? Are they getting tested? (3/7/17)

Read More

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Human Research

View Related Clinical Trials

Study : Research suggests exercise is safe for breast cancer patients at risk for lymphedema

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with, or at high risk for lymphedema after breast cancer

Patients and health care providers are often concerned about how exercise affects lymphedema (swelling in the arm or hand) in breast cancer survivors or other women who have had lymph node biopsy at the time of mastectomy. Research on this topic has been mixed. A new study suggests that exercise after breast cancer treatment does not lead to lymphedema or worsen existing lymphedema. However, because this study was small, more work needs to be done to understand the relationship between exercise and lymphedema in cancer survivors. (2/22/17)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : A step in the development of a new breast cancer risk assessment tool for Hispanic women

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Hispanic women

Current tools used to calculate breast cancer risk make their estimations based on data from non-Hispanic white women and may not accurately predict breast cancer risk in women of other races and ethnicities. With further testing, a new risk assessment tool developed specifically for Hispanic women could more accurately predict breast cancer risk in women who do not have mutations in BRCA or other genes associated with hereditary breast cancer. (02/07/17)

Read More

Relevance: Medium

Strength of Science: Medium-Low

View Related Clinical Trials

Study : Angelina Jolie spoke out on BRCA testing: Did genetic testing increase?

Relevance: Medium

Strength of Science: Medium-Low

View Related Clinical Trials

Most relevant for: People interested in genetic testing for an inherited mutation

Angelina Jolie published an editorial in the New York Times in 2013 about her choice to have a double mastectomy after finding out she was positive for a BRCA1 mutation. Researchers from a recent study claim that her celebrity endorsement of BRCA testing may have missed its target audience (previvors), due to the increase in BRCA testing following publication of the editorial but a decrease in the number of mastectomies performed. However, the study failed to take into account that many women without breast cancer do not pursue mastectomy in the months following genetic testing. (1/4/17)

Read More

Relevance: Medium

Strength of Science: Medium-High

View Related Clinical Trials

Study : Removing ovaries before age 50 may increase the risk of chronic conditions for some women

Relevance: Medium

Strength of Science: Medium-High

View Related Clinical Trials

Most relevant for: Women under 50 years of age who have had or are considering removing their ovaries

Removal of ovaries and fallopian tubes prevents ovarian cancer, but it may come with other health risks. Experts recommend removal of ovaries and fallopian tubes in women at high risk for ovarian cancer due to inherited mutations in BRCA or other genes linked to ovarian cancer risk. For these high-risk women the benefit of ovarian cancer prevention outweighs the risk of long-term complications. Based on a recent study, some researchers feel that for women who are not at increased risk for cancer, the risk for some chronic conditions is too high to consider removal of both ovaries. (11/1/16)

Read More